
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE reported a 13% year-over-year increase in product sales, totaling €163.3 million in 2024, compared to €144.6 million in 2023. The company’s total revenue reached €169.6 million in 2024, reflecting a 10% growth from €153.7 million in the previous year, supported by the recent accelerated approval of Ixchiq by the FDA, which is expected to significantly boost sales. Furthermore, Valneva anticipates Ixchiq sales will surpass €100 million by its third year on the market, with an estimated global market potential for chikungunya vaccines exceeding $500 million annually, underlining a strong future revenue outlook.
Bears say
Valneva SE has projected a significant reduction in its operating cash burn, targeting below €30 million in 2025, a decrease from over €60 million anticipated in 2024. Revenue estimates for 2025 have been revised downward from €222.5 million to €185 million, alongside a lowered earnings per share estimate changing from (€0.53) to (€0.65). Additionally, forecasts for Ixchiq sales have been decreased, with 2024 estimates at €3 million and 2029 estimates reduced from €250 million to €225 million, indicating ongoing challenges in revenue generation within the company's portfolio.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares